Literature DB >> 9561029

Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3.

P R Warfield1, P N Makker, A Raz, J Ochieng.   

Abstract

In this report, we have analyzed the adhesive interactions of a breast carcinoma cell line, BT-549, and its galectin-3-transfected subclone 11-9-1-4 with laminin, collagen IV and fibronectin. We determined that 11-9-1-4 cells adhered much more rapidly (within 1 h of plating) to laminin- and collagen IV-coated wells than the galectin-3 null expressing BT-549 cells. However, after 24 h, both cell lines fully adhered to laminin and collagen IV. Both cell lines also achieved maximum adhesion to fibronectin within 30 min. Not only did 11-9-1-4 express galectin-3 in the usual punctate pattern on its cell surface, it demonstrated a higher surface expression of alpha 6 beta 1 integrin compared to BT-549. The 11-9-1-4 cells were able to invade through matrigel-coated polycarbonate filters at approximately 3 times the rate of BT-549 parental cells. Our data suggest that galectin-3 is essential for adhesion to laminin and collagen IV but not fibronectin by breast carcinoma cells. In addition, galectin-3 expression may modulate the surface expression of some of the integrins specific for laminin and collagen IV adhesion and invasion of basement membrane by breast carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9561029

Source DB:  PubMed          Journal:  Invasion Metastasis        ISSN: 0251-1789


  18 in total

1.  Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions.

Authors:  Amos M Sakwe; Rainelli Koumangoye; Bobby Guillory; Josiah Ochieng
Journal:  Exp Cell Res       Date:  2010-12-24       Impact factor: 3.905

2.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

4.  Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin.

Authors:  Tsutomu Kobayashi; Tatsuo Shimura; Toshiki Yajima; Norio Kubo; Kenichiro Araki; Soichi Tsutsumi; Hideki Suzuki; Hiroyuki Kuwano; Avraham Raz
Journal:  Int J Cancer       Date:  2011-03-29       Impact factor: 7.396

5.  Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin.

Authors:  Trevor A Baptiste; Ashley James; Margaret Saria; Josiah Ochieng
Journal:  Exp Cell Res       Date:  2006-11-16       Impact factor: 3.905

Review 6.  Galectin-3 in angiogenesis and metastasis.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Glycobiology       Date:  2014-08-18       Impact factor: 4.313

7.  The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer.

Authors:  Daniel P Hollern; Jordan Honeysett; Robert D Cardiff; Eran R Andrechek
Journal:  Mol Cell Biol       Date:  2014-06-16       Impact factor: 4.272

8.  Fetuin-A triggers the secretion of a novel set of exosomes in detached tumor cells that mediate their adhesion and spreading.

Authors:  Kurt Watson; Rainelli Koumangoye; Pamela Thompson; Amos M Sakwe; Tina Patel; Siddharth Pratap; Josiah Ochieng
Journal:  FEBS Lett       Date:  2012-08-08       Impact factor: 4.124

Review 9.  Extracellular functions of galectin-3.

Authors:  Josiah Ochieng; Vyacheslav Furtak; Pavel Lukyanov
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

Review 10.  Galectin-3 and metastasis.

Authors:  Yukinori Takenaka; Tomoharu Fukumori; Avraham Raz
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.